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We studied 5555 seminoma patients and 3733 patients with nonseminomatous testicular cancers diagnosed in Southeast England
between 1960 and 2004. For both groups survival improved over time: 10-year relative survival increased from 78% in 1960–1969
to 99% in 1990–2004 for seminomas, and from 55 to 95% for nonseminomas. In the early period mortality was still significantly
increased more than 15 years after diagnosis in both groups, whereas in more recent periods the excess deaths mainly occurred in
the first 5 years after diagnosis. For seminomas, there was a significant excess of cancers of the colon (standardised incidence ratio
(SIR) 2.36; 95% confidence interval (CI) 1.13–4.35), soft tissue (SIR 13.64; CI 1.65–49.28) and bladder (SIR 4.28; CI 2.28–7.31) in
the long term (20þ years after diagnosis), of pancreatic cancer in both the medium (10–19 years) (SIR 2.91; CI 1.26–5.73) and long
term (SIR 5.48; CI 2.37–10.80), of leukaemia in both the short (0–9 years) (SIR 3.01; CI 1.44–5.54) and long term (SIR 4.48; CI
1.64–9.75), and of testis cancer in both the short (SIR 6.69; CI 4.28–9.95) and medium term (SIR 3.96; CI 1.08–10.14). For
nonseminomas, significant excesses were found in the long term for cancers of the stomach (SIR 5.13; CI 1.40–13.13), rectum (SIR
4.49; CI 1.22–11.51) and pancreas (SIR 10.17: CI 3.73–22.13), and for testis cancer in the medium term (SIR 5.94; CI 2.18–12.93).
Leukaemia was significantly increased in the short term (SIR 6.78; CI 2.93–13.36). The better survival observed is largely attributable
to improved treatment, and the trend in reducing the toxicity of therapy should continue to reduce future health risks in testicular
cancer survivors.
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Testicular germ cell cancer occurs predominantly in young
adulthood and is highly curable (Coleman et al, 2003). This high
cure rate heightens concern over the risk of late treatment effects
including second primary cancers (Fossa, 2004; Zagars et al, 2004),
of which an increased incidence has been found following both
radiotherapy and chemotherapy (Travis et al, 2005). This risk may
depend upon specific details of treatment such as the chemother-
apeutic drugs used or choice of radiation dose and field; a previous
study from the Thames Cancer Registry (TCR) based on 859
patients treated with radiotherapy for seminoma between 1961 and
1985 did not find an increase in mortality risks from other causes
(Horwich and Bell, 1994). In this report we extend the previous
TCR study, assessing the overall mortality and incidence of second
primary cancers in 9892 patients with first testis cancer diagnosis
between 1960 and 2004.
PATIENTS AND METHODS
Details of all testicular cancers (ICD-10 code C62) diagnosed
between 1960 and 2004 were extracted from the TCR database.
Of the 9941 testis cancers identified, nine were the contralateral
cancers of bilateral pairs diagnosed on the same day, and 40 were
second primaries diagnosed subsequent to an earlier testicular
cancer. We thus had an index cohort of 9892 first testis cancer
cases. These were subsequently categorised on the basis of their
morphology as seminomas, nonseminomas, or of other/unspeci-
fied type; the latter group excluded lymphomas.
The TCR is a population-based registry covering London and a
large part of Southeast England, with a resident population at the
time of this study of approximately 14 million. Patients registered
at TCR represent a cohort of individuals followed up from cancer
diagnosis to death. Those diagnosed before 1 January 1971 were
followed up actively to obtain death information until 31
December 1982, and were censored at this date. Patients diagnosed
from 1 January 1971 onwards were followed up passively through
the National Health Service (NHS) Central Register, which
provides notification of all deaths routinely to the registry. These
patients were censored at 31 December 2004 (the date up to which
we could assume death information to be essentially complete).
Person-years at risk were calculated from the date of diagnosis
of testicular cancer to the date of the event of interest (either death
or first diagnosis of cancer at a specific site) or to the date of exit
from the study (date of death or loss to follow-up, or censoring
date as defined above, whichever was the earlier).
Relative survival was estimated by the method of Este `ve et al
(1990), comparing observed mortality with expected mortality
derived from life tables for Southeast England (Coleman et al,
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(derived from the same life tables) in each of three periods of
follow-up (0–4, 5–14, and 15þ years after diagnosis) were
compared to give standardised mortality ratios (SMRs). For the
incidence of subsequent cancers, male age/calendar period specific
cancer incidence rates for the TCR region were applied to the
cohort to calculate the expected number of subsequent tumours at
each site. From the observed and expected numbers standardised
incidence ratios (SIRs) were derived. Exact 95% confidence
intervals (CIs) were calculated assuming a Poisson distribution
for the observed numbers. All statistical calculations were
performed using the statistics package Stata (Statacorp, 2003).
RESULTS
Of the 9892 first testicular cancers, 5555 (56.2%) were seminomas,
3733 (37.7%) nonseminomas, and 604 (6.1%) other/unspecified.
Mean ages at diagnosis were 39.3 (s.d. 11.4) years for seminomas,
31.0 (s.d. 10.4) years for nonseminomas, and 45.0 (s.d. 23.3) years
for the other/unspecified group. Figure 1 shows the age distribu-
tions in these three groups. Seminoma cases were in general older
than those with nonseminomas. The relatively small group of
‘other/unspecified’ cases have been excluded from subsequent
analyses. A total of 1590 deaths (820 in seminoma cases and 770
in nonseminomas) occurred during a total of 104622 person–
years of follow-up. Only 51 cases were known to be lost to
follow-up.
Figure 2 shows relative survival in seminomas and nonsemino-
mas for up to 20 years after diagnosis, stratified by period of
diagnosis. In all periods, survival was better in seminomas. For
both groups survival improved over time, particularly for
nonseminomas. Ten-year relative survival estimates increased
from 78% in 1960–1969 to 99% in 1990–2004 for seminomas, and
from 55 to 95% for nonseminomas over the same period.
Table 1 shows SMRs and 95% CIs during the three periods of
follow-up, again stratified by period of diagnosis. In keeping with
the relative survival figures, the SMRs for both types of cancer
decreased over time. In the very early period (1960–1969) a
significantly increased mortality persisted more than 15 years after
diagnosis in both seminomas and nonseminomas. However, in
more recent periods the majority of excess deaths were in the first
5 years after diagnosis. For cases diagnosed between 1990 and
2004, the SMR in this first 5-year period was 1.69 (95% CI 1.36–
2.08) for seminomas and 8.50 (95% CI 7.03–10.19) for non-
seminomas.
The results relating to subsequent cancers are shown in Tables 2
and 3, with length of follow-up stratified into 0–9, 10–19, and
20þ years following diagnosis. A specific cancer site was included
in these tables if the total number of subsequent cancers at this site
exceeded 10. Sites satisfying this criterion were stomach (C16),
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ycolon (C18–C19), rectum (C20–C21), pancreas (C25), lung (C33–
C34), prostate (C61), testis (C62), kidney (C64), bladder (C67),
non-Hodgkin’s lymphoma (C82–C85), and leukaemia (C91–C95).
Also included in the table were malignant neoplasms of ‘other
connective and soft tissue’ (C49), as a means of identifying soft
tissue sarcomas. All remaining sites (with the exception of
nonmelanoma skin cancers (C44), which are poorly recorded)
were grouped into an ‘other’ category.
A total of 409 cancers occurred subsequent to testis cancer
(excluding nonmelanoma skin cancers and testis cancers), 296
after seminomas and 113 after nonseminomas. For seminomas,
there was a significant excess of cancers of the colon, soft tissue
and bladder and of ‘other’ cancers in the long term (20þ years
after diagnosis). In addition, there was an excess of pancreatic
cancer in both the medium (10–19 years) and long term, of
leukaemia in both the short (0–9 years) and long term, and of
testis cancer in both the short and medium term. Lung and ‘other’
cancers were significantly reduced in the short term. For
nonseminomas, significant excesses were found in the long term
for cancers of the stomach, rectum and pancreas, and for testis
cancer in the medium term; leukaemia was significantly raised in
the short term.
Sites included in the above-mentioned ‘other’ group which
showed significant excesses were: anus (C21) (SIR 7.98; CI 1.12–
56.64), bone and articular cartilage other than of limbs (C41) (SIR
25.96; CI 3.66–184.28), renal pelvis (C65) (SIR 17.34; CI 2.44–
123.09), and Hodgkin’s disease (C81) (SIR 12.99; CI 3.25–51.93) in
seminoma patients and C21 (SIR 15.44; CI 2.17–109.58), heart,
mediastinum and pleura (C38) (SIR 40.84; CI 5.75–289.94), C41
(SIR 47.57; CI 6.70–337.69) and skin melanoma (C43) (SIR 4.30; CI
1.08–17.19) in nonseminoma cases. These excesses were all seen
more than 20 years after diagnosis.
DISCUSSION
The data in this report illustrate an overall improvement in
survival during the study period, which is likely to be mainly
because of improvements in treatment, especially the development
of effective combination chemotherapy during the 1970s (Einhorn
Table 1 SMRs by type of testis cancer, period of follow-up, and period of diagnosis
Time since diagnosis (years)
0–4 5–14 15+
95% CI 95% CI 95% CI
Type Period of diagnosis Deaths SMR L U Deaths SMR L U Deaths SMR L U
Seminomas 1960–1969 94 8.62 6.96 10.54 51 1.89 1.41 2.48 91 2.55 2.05 3.13
1970–1979 86 5.76 4.60 7.11 47 1.25 0.92 1.66 104 0.99 0.81 1.20
1980–1989 69 2.59 2.02 3.28 79 0.99 0.78 1.23 51 0.93 0.69 1.22
1990–2004 91 1.69 1.36 2.08 57 1.00 0.76 1.30 — — — —
Nonseminomas 1960–1969 126 56.76 47.28 67.58 11 2.10 1.05 3.75 22 4.44 2.79 6.73
1970–1979 241 45.13 39.61 51.20 25 1.66 1.07 2.44 52 1.17 0.87 1.53
1980–1989 107 15.09 12.37 18.24 30 1.37 0.92 1.95 21 1.31 0.81 2.01
1990–2004 117 8.50 7.03 10.19 18 1.26 0.75 2.00 — — — —
SMRs¼standardised mortality ratios; CI¼confidence interval; L¼lower; U¼upper.
Table 2 SIRs for subsequent cancers by period of follow-up – seminomas
Time since diagnosis (years)
0–9 10–19 20+
95% CI 95% CI 95% CI
Site No. SIR L U No. SIR L U No. SIR L U
Stomach 8 1.60 0.69 3.15 1 0.24 0.01 1.32 4 1.86 0.51 4.76
Colon 7 0.88 0.35 1.81 6 0.83 0.30 1.81 10 2.36 1.13 4.35
Rectum 5 1.13 0.37 2.65 4 1.03 0.28 2.64 5 2.38 0.77 5.56
Pancreas 3 0.96 0.20 2.82 8 2.91 1.26 5.73 8 5.48 2.37 10.80
Lung 9 0.42 0.19 0.80 16 0.86 0.49 1.40 13 1.37 0.73 2.34
Soft tissue 1 1.81 0.05 10.11 2 5.82 0.70 21.01 2 13.64 1.65 49.28
Prostate 9 0.75 0.34 1.43 14 1.02 0.56 1.72 17 1.68 0.98 2.68
Testis 24 6.69 4.28 9.95 4 3.96 1.08 10.14 1 6.25 0.16 34.82
Kidney 3 1.08 0.22 3.14 2 0.84 0.10 3.04 2 1.65 0.20 5.97
Bladder 6 0.95 0.35 2.07 3 0.53 0.11 1.56 13 4.28 2.28 7.31
NHL 8 1.53 0.66 3.01 5 1.36 0.44 3.17 2 1.18 0.14 4.27
Leukaemia 10 3.01 1.44 5.54 1 0.39 0.01 2.18 6 4.48 1.64 9.75
Other
a 16 0.54 0.31 0.88 15 0.65 0.36 1.07 23 2.01 1.28 3.02
Total
a 109 1.04 0.85 1.25 81 0.91 0.72 1.13 106 2.18 1.79 2.64
NHL¼Non-Hodgkin’s lymphoma; SIRs¼standardised incidence ratios.
aExcluding nonmelanoma skin cancer.
Testis cancer mortality
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first 5 years after diagnosis was evident even in comparisons of
those diagnosed between 1980 and 1989 with those diagnosed
between 1990 and 2004 (Table 1). This may be owing to the trend to
presentation of germ cell tumours at an earlier stage (Sonneveld
et al, 1999; Powles et al, 2005). For seminomas the SMR improved
from 2.59 (95% CI 2.02–3.28) to 1.69 (CI 1.36–2.08) and for
nonseminomas from 15.09 (CI 12.37–18.24) to 8.50 (CI 7.03–10.19).
In those diagnosed in the 1960s significantly raised SMRs extended
more than 15 years after diagnosis, consistent with the time course
reported for late radiation effects (Zagars et al, 2004). These long-
term risks do not appear to extend to those diagnosed after 1970.
However, these findings should be interpreted with caution in view
of the limited number of patients with long-term follow-up.
Fossa et al (2004) reported mortality rates in patients treated in
Norway below age 56 years between 1962 and 1997, and found that
among those not dying from malignant germ cell tumours there
were significantly increased SMRs for diseases of the circulatory
system, benign gastrointestinal disorders, and non germ cell
malignancies. However, the mortality from non germ cell cancers
was higher in those treated between 1970 and 1997 than in those
treated in the 1960s.
Treatment patterns for seminomas have been somewhat distinct
from those for nonseminomas. In the past most seminomas were
managed with radiotherapy following orchidectomy whereas with
nonseminomas, since the development of effective chemotherapy
during the late 1970s, radiotherapy has been used increasingly
rarely (Horwich et al, 2006). The radiation field most commonly
used in seminoma patients included the para-aortic and ipsilateral
pelvic lymph nodes. However, particularly during the early period
of the cohort, selected patients also had radiotherapy to
mediastinal and supraclavicular lymph nodes (Zagars and Babaian,
1987; Hanks et al, 1992). After seminomas we found an increased
risk of both leukaemia (SIR 3.01; CI 1.44–5.54) and testis cancer
(SIR 6.69; CI 4.28–9.95) in the first decade after diagnosis. In the
second decade there were significantly increased risks for cancers
of the pancreas (SIR 2.91; CI 1.26-5.73) and testis (SIR 3.96; CI
1.08-10.14). After more than 20 years there were significantly
increased SIRs for pancreatic cancer (SIR 5.48; CI 2.37–10.80),
colon cancer (2.36; CI 1.13–4.35), soft tissue sarcoma (SIR 13.64;
CI 1.65–49.28), bladder cancer (SIR 4.28; CI 2.28–7.31), and
leukaemia (SIR 4.48; CI 1.64–9.75). Considering all cancer sites
combined, we found no overall excess risk in the first two decades,
but more than 20 years from diagnosis the risk of developing a
second cancer was doubled to 2.18 (95% CI 1.79–2.64).
Hay et al (1984), analysing second cancer risk in 547 patients
treated with radiotherapy for testis cancer between 1950 and 1969
in Scotland, found an increased second cancer risk peaking 15–19
years after treatment. A long-term study from Norway of 365
seminoma patients treated with radiotherapy (Fossa et al, 1989)
found an excess of lung cancer but not of leukaemia. A similar
study from the MD Anderson Hospital (Zagars et al, 2004) found a
cancer specific SMR of 1.9, which again was only significant at time
periods more than 15 years after treatment. Second testicular
cancers are likely to be because of factors other than treatment,
and in fact the incidence is reduced after chemotherapy (Oliver
et al, 2005), or after direct radiotherapy to the testis (Read, 1987;
Dieckmann et al, 1993).
In patients treated for nonseminomas of the testis, we found an
increased risk of developing leukaemia during the first decade (SIR
6.78; CI 2.93–13.36). The only significant excess risk observed
during the second decade was for testis cancer (SIR 5.94; CI 2.18–
12.93). After 20 years from diagnosis there were significant
excesses of stomach (SIR 5.13; CI 1.40–13.13), rectum (SIR 4.49;
CI 1.22–11.51) and pancreas cancers (SIR 10.17; CI 3.73–22.13).
For all sites combined there was again a significant excess of
second cancers only after more than 20 years from diagnosis (SIR
1.97; CI 1.40–2.69). In the past, these patients were often treated
with both chemotherapy and radiotherapy (Peckham et al, 1979),
making it difficult to relate risk to specific treatment modalities.
Our findings are largely consistent with those reported in long-
term survivors of testicular cancer from 14 population-based
cancer registries in North America and Europe (Travis et al, 2005).
As here, the relative risk of second cancers 10 years or more after
diagnosis was approximately doubled for both seminomas and
nonseminomas. In addition to the sites for which we observed an
excess, they found significant excesses for cancers of the pleura,
lung and oesophagus. These workers also found lower risk of
second cancers in patients with nonseminoma diagnosed after
1975. A nested case–control analysis from eight population-based
cancer registries suggested that leukaemia risk after testicular
cancer was related to both radiation dose to active bone marrow,
Table 3 SIRs for subsequent cancers by period of follow-up–non seminomas
Time since diagnosis (years)
0–9 10–19 20+
95% CI 95% CI 95% CI
Site No. SIR L U No. SIR L U No. SIR L U
Stomach 0 0.00 0.00 3.26 1 0.87 0.02 4.84 4 5.13 1.40 13.13
Colon 3 1.58 0.33 4.61 4 1.93 0.53 4.95 4 2.41 0.66 6.17
Rectum 1 0.94 0.02 5.26 2 1.72 0.21 6.23 4 4.49 1.22 11.51
Pancreas 0 0.00 0.00 5.05 2 2.50 0.30 9.03 6 10.17 3.73 22.13
Lung 4 0.89 0.24 2.28 3 0.62 0.13 1.80 5 1.45 0.47 3.38
Soft tissue 0 0.00 0.00 14.76 1 6.74 0.17 37.55 0 0.00 0.00 52.70
Prostate 2 0.95 0.11 3.42 2 0.66 0.08 2.38 3 0.80 0.16 2.33
Testis 4 1.52 0.41 3.88 6 5.94 2.18 12.93 0 0.00 0.00 20.49
Kidney 3 4.00 0.82 11.69 0 0.00 0.00 4.55 1 1.75 0.04 9.77
Bladder 3 2.11 0.44 6.17 2 1.33 0.16 4.82 1 0.93 0.02 5.16
NHL 2 1.03 0.12 3.72 1 0.64 0.02 3.55 2 2.30 0.28 8.30
Leukaemia 8 6.78 2.93 13.36 1 1.09 0.03 6.06 0 0.00 0.00 6.47
Other
a 11 1.13 0.56 2.02 8 0.96 0.41 1.89 9 1.69 0.77 3.20
Total
a 41 1.40 1.00 1.90 33 1.20 0.83 1.69 39 1.97 1.40 2.69
NHL¼Non-Hodgkin’s lymphoma.
aExcluding nonmelanoma skin cancer.
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risk was threefold after a total cumulative cisplatin dose of 650mg,
which would commonly be achieved with the standard four cycles
of chemotherapy. An analysis of 1909 cases in The Netherlands
diagnosed from 1971 to 1985 (van Leeuwen et al, 1993), based on
more detailed treatment information, was able to link an increased
risk of stomach cancer to radiation; this study found no excess of
second malignancies after chemotherapy.
Our study has a number of shortcomings. It is based on cancer
registry data, which contain limited treatment information largely
confined to initial management and lacking detail of specific
drugs, radiation doses, and radiation fields. Also, there may be
under-reporting of second cancers in those who leave the registry
catchment area. In the majority of such cases, the registry would
not be informed of emigration, nor receive notification of
subsequent cancers. This would lead to an underestimation of
the risk of subsequent cancer, so that SIRs will be conservative.
Additionally, as the data were extracted in 2005, incident cancers
to the end of 2004 would still be a few percent incomplete, which
again would tend to lead to an underestimation of SIRs, although
here restricted to the short-term estimates.
In modern oncology practice, with better perception of
individual prognosis, the overall burden of treatment for patients
with testicular germ cell cancer has reduced considerably
(Horwich et al, 2006). For example, many patients with stage I
cancers are managed by surveillance after orchidectomy and thus
mainly avoid both radiotherapy and chemotherapy (Warde et al,
2002; Horwich et al, 2006). This trend of reducing the toxicity of
management should continue to reduce health risks in testicular
cancer survivors.
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